Serum endostatin predicts tumor vascularity in hepatocellular carcinoma
β Scribed by Mesut Tez; Selda Tez
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 45 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
We agree that the measurement of serum endostatin can predict tumor vascularity and may serve as a promising tool in antiangiogenic therapy for patients with HCC.
At the same time, the 184-amino acid proteolytic fragment of the carboxy terminus of C18, endostatin, has been identified as a potent endogenous inhibitor of angiogenesis. The liver is the main source of endostatin in humans and mice. Hepatocytes are a major source of C18 expression in liver. 2 Therefore, liver resection (especially major hepatic resection) may alter postoperative endostatin levels but to our knowledge there are no data published to date in the literature regarding this matter.
We conclude that endogeneous endostatin release must be considered after liver resection.
π SIMILAR VOLUMES
## Abstract ## Purpose To evaluate ferumoxideβenhanced MR imaging findings of hepatocellular carcinomas (HCCs) in correlation with the histologic tumor grades and the tumor vascularity evaluated by CT hepatic arteriography (CTHA) and CT during arterial portography (CTAP) combined. ## Materials an
Vascular invasion and high histologic grade predict poor outcome after surgical resection or liver transplantation for hepatocellular carcinoma (HCC). Despite the known association between tumor size and vascular invasion, a proportion of patients with large tumors can be treated surgically with exc